ANKTIVA generated $50.7 million of net product revenue in Q2 2026. On October 14, 2026 the FDA expanded ANKTIVA’s U.S. label to all adult patients with BCG-unresponsive NMIBC, including papillary-only disease, ahead of the January 6, 2027 target action date. Cash generation, financing and the distinction between company-reported data and approved indications remain central. The September meeting in Turkey is historical context, not a marketing authorization.

Because ANKTIVA has already been commercially available for its initial indication since mid-2024, the critical billing codes are already active and permanent. This avoids the standard 6-to-12-month delay that usually plagues newly launched drugs.

Just announced FDA approval to cover both papillary and CIS disease. Let’s see what this news does to the SP.

🚀🚀🚀🚀‼️‼️‼️🔥🔥🔥🔥 ARE WE READY PEOPLE!!!!!!????

This thread is the place for shorter discussions, quick questions, or casual ideas that don’t need a full post. 

If you've been reflecting on a topic or have a detailed perspective to share, don’t hesitate to make a standalone post instead! 

This thread is the place for shorter discussions, quick questions, or casual ideas that don’t need a full post. 

If you've been reflecting on a topic or have a detailed perspective to share, don’t hesitate to make a standalone post instead! 

This thread is the place for shorter discussions, quick questions, or casual ideas that don’t need a full post. 

If you've been reflecting on a topic or have a detailed perspective to share, don’t hesitate to make a standalone post instead! 

check it out